The C-terminus of p63 contains multiple regulatory elements with different functions

Cell Death and Disease

Volumn 1, Issue 1, 2010, Pages

  Straub, W E ^a   Weber, T A ^a   Schafer B ^a   Candi, E ^b   Durst, F ^a   Ou, H D ^a   Rajalingam, K ^a   Melino, G ^b,c   Dotsch V ^a  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

auto inhibition; p63; sumoylation; transcriptional regulation

Indexed keywords

ALANINE; AMINO ACID; PROTEIN P63; ISOPROTEIN; TP63 PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; TUMOR SUPPRESSOR PROTEIN;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SUMOYLATION; CHEMISTRY; GENETICS; METABOLISM; MOLECULAR GENETICS; MUTATION; PROTEIN TERTIARY STRUCTURE; TUMOR CELL LINE;

AMINO ACID SEQUENCE; CELL LINE, TUMOR; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; PROTEIN BINDING; PROTEIN ISOFORMS; PROTEIN STRUCTURE, TERTIARY; SUMOYLATION; TRANS-ACTIVATORS; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEINS;

EID: 77957285567     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2009.1     Document Type: Article

References (41)

1. Trink B, Okami K, Wu L, Sriuranpong V, Jen J, Sidransky D. A new human p53 homologue. Nat Med 1998; 4: 747-748.
2. Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dotsch V et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominantnegative activities. Mol Cell 1998; 2: 305-316. (Pubitemid 128379271)
3. Osada M, Ohba M, Kawahara C, Ishioka C, Kanamaru R, Katoh I et al. Cloning and functional analysis of human p51, which structurally and functionally resembles p53. Nat Med 1998; 4: 839-843. (Pubitemid 28331028)
4. Senoo M, Seki N, Ohira M, Sugano S, Watanabe M, Inuzuka S et al. A second p53- related protein, p73L, with high homology to p73. Biochem Biophys Res Commun 1998; 248: 603-607. (Pubitemid 28404468)
5. Flores ER, Tsai KY, Crowley D, Sengupta S, Yang A, McKeon F et al. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 2002; 416: 560-564. (Pubitemid 34288861)
6. Flores ER, Sengupta S, Miller JB, Newman JJ, Bronson R, Crowley D et al. Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell 2005; 7: 363-373. (Pubitemid 40544653)
7. Senoo M, Manis JP, Alt FW, McKeon F. p63 and p73 are not required for the development and p53-dependent apoptosis of T cells. Cancer Cell 2004; 6: 85-89. (Pubitemid 38903164)
8. Keyes WM, Vogel H, Koster MI, Guo X, Qi Y, Petherbridge KM et al. p63 heterozygous mutant mice are not prone to spontaneous or chemically induced tumors. Proc Natl Acad Sci USA 2006; 103: 8435-8440. (Pubitemid 43838473)
9. Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, Bronson RT et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 1999; 398: 714-718. (Pubitemid 29197650)
10. Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR, Bradley A. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 1999; 398: 708-713. (Pubitemid 29197649)
11. Senoo M, Pinto F, Crum CP, McKeon F. p63 Is essential for the proliferative potential of stem cells in stratified epithelia. Cell 2007; 129: 523-536. (Pubitemid 46660965)
12. Suh EK, Yang A, Kettenbach A, Bamberger C, Michaelis AH, Zhu Z et al. p63 protects the female germ line during meiotic arrest. Nature 2006; 444: 624-628. (Pubitemid 44864440)
13. Koster MI, Dai D, Marinari B, Sano Y, Costanzo A, Karin M et al. p63 induces key target genes required for epidermal morphogenesis. Proc Natl Acad Sci USA 2007; 104: 3255-3260. (Pubitemid 46364146)
14. Koster MI, Kim S, Mills AA, DeMayo FJ, Roop DR. p63 is the molecular switch for initiation of an epithelial stratification program. Genes Dev 2004; 18: 126-131. (Pubitemid 38141780)
15. Serber Z, Lai HC, Yang A, Ou HD, Sigal MS, Kelly AE et al. A C-terminal inhibitory domain controls the activity of p63 by an intramolecular mechanism. Mol Cell Biol 2002; 22: 8601-8611. (Pubitemid 35397175)
16. Ozaki T, Naka M, Takada N, Tada M, Sakiyama S, Nakagawara A. Deletion of the COOH-terminal region of p73alpha enhances both its transactivation function and DNAbinding activity but inhibits induction of apoptosis in mammalian cells. Cancer Res 1999; 59: 5902-5907. (Pubitemid 30004948)
17. Huang YP, Wu G, Guo Z, Osada M, Fomenkov T, Park HL et al. Altered sumoylation of p63alpha contributes to the split-hand/foot malformation phenotype. Cell Cycle 2004; 3: 1587-1596. (Pubitemid 40521413)
18. Ghioni P, D0Alessandra Y, Mansueto G, Jaffray E, Hay RT, Mantia GL et al. The protein stability and transcriptional activity of p63alpha are regulated by SUMO-1 conjugation. Cell Cycle 2005; 4: 183-190. (Pubitemid 41038949)
19. Minty A, Dumont X, Kaghad M, Caput D. Covalent modification of p73alpha by SUMO-1. Two-hybrid screening with p73 identifies novel SUMO-1-interacting proteins and a SUMO- 1 interaction motif. J Biol Chem 2000; 275: 36316-36323.
20. Coutandin D, Löhr F, Niesen F, Ikeya T, Weber T, Schäfer B et al. Conformational stability and activity of p73 require a second helix in the tetramerization domain. Cell Death Differ 2009; 16: 1582-1589.
21. Ross S, Best JL, Zon LI, Gill G. SUMO-1 modification represses Sp3 transcriptional activation and modulates its subnuclear localization. Mol Cell 2002; 10: 831-842. (Pubitemid 35335638)
22. Gill G. Something about SUMO inhibits transcription. Curr Opin Genet Dev 2005; 15: 536-541. (Pubitemid 41262410)
23. Melchior F, Schergaut M, Pichler A. SUMO: ligases, isopeptidases and nuclear pores. Trends Biochem Sci 2003; 28: 612-618. (Pubitemid 38352808)
24. Muller S, Hoege C, Pyrowolakis G, Jentsch S. SUMO, ubiquitins mysterious cousin. Nat Rev Mol Cell Biol 2001; 2: 202-210.
25. Lyst MJ, Stancheva I. A role for SUMO modification in transcriptional repression and activation. Biochem Soc Trans 2007; 35: 1389-1392.
26. Ying H, Chang DL, Zheng H, McKeon F, Xiao ZX. DNA-binding and transactivation activities are essential for TAp63 protein degradation. Mol Cell Biol 2005; 25: 6154-6164. (Pubitemid 40946565)
27. Johnson ES, Gupta AA. An E3-like factor that promotes SUMO conjugation to the yeast septins. Cell 2001; 106: 735-744. (Pubitemid 32900664)
28. Pichler A, Gast A, Seeler JS, Dejean A, Melchior F. The nucleoporin RanBP2 has SUMO1 E3 ligase activity. Cell 2002; 108: 109-120. (Pubitemid 34137016)
29. Mahajan R, Delphin C, Guan T, Gerace L, Melchior F. A small ubiquitin-related polypeptide involved in targeting RanGAP1 to nuclear pore complex protein RanBP2. Cell 1997; 88: 97-107. (Pubitemid 27180334)
30. Nicholls CD, McLure KG, Shields MA, Lee PW. Biogenesis of p53 involves cotranslational dimerization of monomers and posttranslational dimerization of dimers. Implications on the dominant negative effect. J Biol Chem 2002; 277: 12937-12945. (Pubitemid 34952661)
31. Davison TS, Nie X, Ma W, Lin Y, Kay C, Benchimol S et al. Structure and functionality of a designed p53 dimer. J Mol Biol 2001; 307: 605-617. (Pubitemid 33027680)
32. Calabro V, Mansueto G, Parisi T, Vivo M, Calogero RA, La Mantia G. The human MDM2 oncoprotein increases the transcriptional activity and the protein level of the p53 homolog p63. J Biol Chem 2002; 277: 2674-2681. (Pubitemid 34953294)
33. Kadakia M, Slader C, Berberich SJ. Regulation of p63 function by Mdm2 and MdmX. DNA Cell Biol 2001; 20: 321-330. (Pubitemid 32692435)
34. Kojima T, Ikawa Y, Katoh I. Analysis of molecular interactions of the p53-family p51(p63) gene products in a yeast two-hybrid system: homotypic and heterotypic interactions and association with p53-regulatory factors. Biochem Biophys Res Commun 2001; 281: 1170-1175. (Pubitemid 32924541)
35. Little NA, Jochemsen AG. Hdmx and Mdm2 can repress transcription activation by p53 but not by p63. Oncogene 2001; 20: 4576-4580. (Pubitemid 32772440)
36. Wang X, Arooz T, Siu WY, Chiu CH, Lau A, Yamashita K et al. MDM2 and MDMX can interact differently with ARF and members of the p53 family. FEBS Lett 2001; 490: 202-208. (Pubitemid 32171940)
37. Rossi M, Aqeilan RI, Neale M, Candi E, Salomoni P, Knight RA et al. The E3 ubiquitin ligase Itch controls the protein stability of p63. Proc Natl Acad Sci USA 2006; 103: 12753-12758. (Pubitemid 44298633)
38. Rossi M, De Simone M, Pollice A, Santoro R, La Mantia G, Guerrini L et al. Itch/AIP4 associates with and promotes p63 protein degradation. Cell Cycle 2006; 5: 1816-1822. (Pubitemid 44435325)
39. Reid G, Hubner MR, Metivier R, Brand H, Denger S, Manu D et al. Cyclic, proteasomemediated turnover of unliganded and liganded ERalpha on responsive promoters is an integral feature of estrogen signaling. Mol Cell 2003; 11: 695-707. (Pubitemid 36385123)
40. Rinne T, Bolat E, Meijer R, Scheffer H, Bokhoven Hv. Spectrum of p63 mutations in a selected patient cohort affected with ankyloblepharon-ectodermal defects-cleft lip/palate syndrome (AEC). Am J Med Genet Part A 2009; 149: 1948-1951.
41. Duijf PH, van Bokhoven H, Brunner HG. Pathogenesis of split-hand/split-foot malformation. Hum Mol Genet 2003; 12 (Spec No 1): R51-R60. (Pubitemid 36442954)